New 4‑Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure−activity Relationships

The study focuses on developing antiviral compounds targeting human adenovirus (HAdV), a significant concern for immunocompromised patients due to the lack of effective treatments. The researchers designed and synthesized a library of small molecules and tested them for antiviral activity. From this...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Céspedes, Javier, Martínez Aguado, Pablo, Vega-Holm, Margarita, Serna-Gallego, Ana, Candela, José Ignacio, Marrugal-Lorenzo, José Amtonio, Pachón, Jerónimo, Iglesias-Guerra, Fernando, Vega-Pérez, José Manuel
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universidad Loyola Andalucía
Repositorio:Brújula
OAI Identifier:oai:repositorio.uloyola.es:20.500.12412/7124
Acceso en línea:https://hdl.handle.net/20.500.12412/7124
Access Level:acceso abierto
Palabra clave:Adenovirus, antiviral compounds, chemical library, 2-phenylpiperazines
Adenovirus
Antiviral compounds
Chemical library
2-phenylpiperazines
Descripción
Sumario:The study focuses on developing antiviral compounds targeting human adenovirus (HAdV), a significant concern for immunocompromised patients due to the lack of effective treatments. The researchers designed and synthesized a library of small molecules and tested them for antiviral activity. From this collection, they identified six phenylpiperazine‑based compounds that strongly inhibited HAdV infection. Beyond their effect on adenovirus, these molecules were also effective against human cytomegalovirus (HCMV), suppressing viral replication at low micromolar concentrations while exhibiting minimal cytotoxicity in host cells. Further biological analyses revealed that the compounds interfere with different stages of the viral life cycles of both HAdV and HCMV. Overall, the findings highlight these phenylpiperazine derivatives as promising candidates for developing a new class of antiviral drugs with activity against multiple DNA viruses, especially relevant for treating infections in vulnerable patient populations.